HER-2/neu expression in locally advanced breast carcinomas: Pre-and post-neoadjuvant chemotherapy

Breast Cancer

Volumn 12, Issue 4, 2005, Pages 294-298

  Ruhul Quddus, M ^a   James Sung, C ^a   Zhang, Cunxian ^a   Pasqueriello, Terese ^a   Eklund, Meryle ^a   Steinhoff, Margaret M ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Breast cancer; HER 2 neu; Neo adjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADJUVANT THERAPY; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA; CASE CONTROL STUDY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 33644836395     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.2325/jbcs.12.294     Document Type: Article

References (20)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235:177-182, 1987. (Pubitemid 17231334)
2. Hoff ER, Tubb RR, Myles JL, Procop GW: HER-2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 117:916-921, 2002. (Pubitemid 34564348)
3. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413-428, 1998. (Pubitemid 28524507)
4. Wang J, Buchholz TA, Middleton LP, et al: Assessment histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neo-adjuvant chemotherapy in patients with breast carcinoma. Cancer 94:3107-3114, 2002. (Pubitemid 34685488)
5. Paik S, Park C: HER-2 and choice of adjuvant chemotherapy in breast cancer. Semin Oncol 28:332-335, 2000.
6. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of Trastuzumab as a single agent in firstline treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002. (Pubitemid 34111379)
7. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-pl85HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, School S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999. (Pubitemid 29415219)
9. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-pl85HER2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J Clon Oncol 14:737-744, 1996.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783-792, 2001. (Pubitemid 32222155)
11. Cooke T, Reeves J, Lanigan A, Stanton P: HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12(suppl 1):S23-28, 2001. (Pubitemid 32750581)
12. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L: Correlation between HER-2/neu and response to neo-adjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:1758-1765, 2003. (Pubitemid 36350719)
13. Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G: Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against cerbB2 protein domains. Histopathology 43:354-362, 2003. (Pubitemid 37249149)
14. Cardoso F, Piccart MJ, Durbecq V, Di Leo A: Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 3:247-257, 2002. (Pubitemid 35423144)
15. McKeage K, Perry CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62:209-243, 2002. (Pubitemid 34169431)
16. Yamauchi H, Stearns V, Hayes DF: The role of cerbB-2 as a predictive factor in breast cancer. Breast Cancer 8:171-183, 2001.
17. Lo SS, Wang HC, Shyr YM, Lui WY: Can hormone receptor status of primary breast cancer be altered by neo-adjuvant chemotherapy? J Surg Oncol 57:94-96, 1994.
18. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B: The effect of neo-adjuvant chemotherapy on estrogen and progesterone receptor expression and hormone status in breast cancer. Am J Surg 348-350, 2003. (Pubitemid 38368608)
19. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirill F, Bolsi G, Bertoli, Alquati P, Dogliotti L: Effect of neo-adjuvant chemotherapy on Ki67 labeling index, c-erbB-2 expression and steroid hormone receptor status in human breast cancers. Anticancer Res 16:3105-3110, 1996. (Pubitemid 26390257)
20. Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H: Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO Hercep Test. Am J Clin Pathol 118:693-698, 2002. (Pubitemid 37046313)